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Where we are in Organised




- lead radiologist im Slovenian breast cancer screening
DORA
KADIVEC Maksimiljan 
-head and lead radiologist im Slovenian breast cancer
screening DORA
Senološka sekcija november 2017
• EU parlament 2003
- encouraged the Member states to implement Organised Breast cancer screening
programms to lower mortality rate for 25%
- SLOVENIA began 2008
• European guidelines for quality assurance in breast cancer screening and
diagnosis, 2006 last update (fourth edition) by European Commission . 
IARC – International Agency for Research on Cancer
• ECIBC- European commission initiative on breast cancer, 
IARC- International
Agency for Research on 
Cancer
B Lauby-Secretan,  C Scoccianti, D Loomis, LB Tallaa, V Bouvard, F Bianchini, K Straif. Breast-Cancer Screening —
Viewpoint of the IARC Working Group. International Agency for Research on Cancer Handbook Working Group. N 
Engl J Med 2015; 
In 2016 they published










Screening 50-69 y with mmg









Increases in situ 








Sufficient evidence Inadequate evidenceLimited evidence
in
dense breast
B Lauby-Secretan,  C Scoccianti, D Loomis, LB Tallaa, V Bouvard, F Bianchini, K Straif. Breast-Cancer Screening — Viewpoint
of the IARC Working Group. International Agency for Research on Cancer Handbook Working Group. N Engl J Med 2015; 
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• False positive results
- 20% (10 screens between 50 and 70 years)
• Overdiagnosis : 6,5% (1-10%)
- sufficient evidence that overdiagnostis does exist and mmg can detect
BC that would never have been diagnosed or never have caused harm if
woman had not been screened (overdiagnosis)
• Radiation induced death from BC: 1-10/100.000 
women
- 100 x less than breast cancer deaths prevented by screening
The most important harms 
associated with early detection of breast cancer 
through mammographic screening are:
ECIBC- European
Commission Initiative on 
Breast Cancer
• To harmonise and improve breast cancer care in EU
• To develop up-to-date evidence-based recommendations 
for BC screening and dignosis
• To develop a European quality assurance (QA) scheme for 
Breast Cancer Services. 
Screening of average
risk womenMMG
50-69y. Strong recommended for
Strong recommendation against the intervention
Conditional recommendation against the intervention
Conditional recommendation for either the intervention or the comparison
Conditional recommendation for the intervention
Strong recommendation for the intervention

















ECIBC- European commission initiative
on breast cancer screening recommandations
moderate certainty in the evidence
moderate certainty in the evidence
Screening of average
risk women
Strong recommendation against the intervention
Conditional recommendation against the intervention
Conditional recommendation for either the intervention or the comparison
Conditional recommendation for the intervention














((very low certainty in the evidence)
ECIBC- European commission initiative








Strong recommendation against the intervention
Conditional recommendation against the intervention
Conditional recommendation for either the intervention or the comparison
Conditional recommendation for the intervention















screening with MR +MMG
vs. MMG alone 
Not implementing 
screening with HHUS +MMG
vs. MMG alone 
Not implementing 
screening with ABUS +MMG









DBT + DM 
or DM alone
ECIBC- European commission initiative





Status Interval Free of charge Invitation letter
Finland 1987 50-69 Nationwide
Rollout complete
2 yes yes
France 2004 50-74 Nationwide
Rollout complete
2 yes yes
Germany 2005 50-69 Nationwide
Rollout complete
2 yes yes





Netherlands 1989 50-75 Nationwide
Rollout complete
2 yes yes
Sweden 1986 40-74 Nationwide
Rollout complete
1,5-2 yes yes
United Kingdom 1988 50-70 Nationwide
Rollout complete
3 yes yes
Slovenia 2008 50-69 Nationwide
Rollout ongoing
2 yes yes
IARC Cancer screening in European Union. Report on implementation of counsil recommendation on cancer screening; Reprint May 2017
Organised screening in EU
* From 45‐74y only in 2 regions









Finland 100% Yes Yes Mx 83%
France 97% Yes* Yes Mx(CBE) 51%
Germany 100% Yes Yes Mx 56%
Italy 80% Yes Yes Mx 55%
Netherlands 100% Yes Yes Mx 80%
Sweden 100% Yes Yes Mx 73%
United 
Kingdom
100% Yes Yes Mx 71%
Slovenia 100% Yes Yes Mx 82%
*In France only negative mammograms on first reading are double read, which is 90%
IARC Cancer screening in European Union. Report on implementation of counsil recommendation on cancer screening; Reprint May 2017










Finland 2,6% 4,8% 12,5% 5,6
France 9,4% 13,4% 15,1% 6,7
Germany 4,6% 9,3% 19,6% 6,1
Italy 5,8% 10% 15,9% 4,3
Netherlands 2,3% 6,4% 23,4% 6,0
Sweden 2,4% 2,9% 14,7% 6,1
United
Kingdom
3,9% 7% 20,4% 8,4
Slovenia
(2013)
3,4% 5,8% 33,1% 6,1
IARC Cancer screening in European Union. Report on implementation of counsil recommendation on cancer screening; Reprint May 2017
Organised screening in EU
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F Sardanelli et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 
national breast radiology bodies from… Eu Radiol. 2017; 27(7): 2737–2743. 
• Mammography remains the main tool for population-based mass 
screening. 
Digital mammography is the first priority
• Increasing evidence in favor of digital breast tomosynthesis (DBT) as a 
screening tool. (status of “future routine mammography” in the screening 
setting). 
• Not enough evidence for HHUS,ABUS,MR as addition to mammography
in dense breasts (asymptomatic, mmg negative)
IN CONCLUSION:
IARC,ECIBC,EUSOBI
F Sardanelli et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 




For screening mammography from 50 - 69 years of age; 
Conditional: 
For extension up to 70–74 years, biannually
For extension from 45–49 years, annually
Against: 
Extension from 40–44 years of age
SCREENING RECOMMANDATIONS (ECICB):
F Sardanelli et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 
national breast radiology bodies from… Eur Radiol. 2017; 27(7): 2737–2743. 
IN CONCLUSION:
IARC,ECIBC,EUSOBI
- Available data did not allow the IARC working group to define an 
optimal screening interval
- However, the majority of European countries opted for:
 Biannual screening over 50 years of age
 Annual screening in 40- to 49-year-old women if they are
invited





 Increases the detection rate 
 Synthetic 2D view solve the problem of an increased radiation exposure
DBT-
 Varied evidence on the recall and false positive rates
 Increase cost for DBT over DM
 increase in reading time 
 costs of the technology and the data storage
Before introducing DBT in BC screening outside trials
 Statistically relevant evidence of reduction in :
 the interval cancer rate
 incidence of advanced cancer 
 breast cancer mortality 










BREAST CANCER SCREENING 


































Target population (50-69) 2008: 243 00
























• conferences: consensus, preoperative, postoperative
• daily, weekly quality control of mammography machines
• no clinical examination
• setting of an adequate information system

















































































































Image > PACS > ORQA > Report
Medical Physicist‘s view



































Performance indicator Programme DORA EU acceptable EU desirable
value level level
Proportion of women invited that attend for 
screening 77,5% > 70% > 75%
Coverage of eligible women
76% / /
Proportion of women recalled for further 
assessment
Initial screening 
examinations 5,4% < 7% < 5%
Subsequent screening 
examinations 1,6% < 5% < 3%
Breast cancer  detection rate per 1000 
screened       
Initial screening 
examinations 6.7/1000 6,8/1000 > 6,8/1000
Subsequent screening 
examinations 4.5/1000 3.4/1000 > 3.4/1000
Performance indicators in Slovenian breast cancer screening programme 
2016
Proportion of invasive screen - detected 
cancers that are node negative
Initial screening 
examinations 70,6% -- > 70%
Subsequent screening 
examinations 76,4% 75% > 75%
7
Proportion of invasive screen - detected 
cancers that are <= 10 mm in size
Initial screening 
examinations 38,8% / >= 25%
Subsequent screening 
examinations 32,7% >= 25% >= 30%
Interval cancer rate as a proportion of the 
underlying, expected, breast cancer 
incidence rate in the absence of screening
Within the first year (0-
11 months) 20% 30% < 30%
Within the second year 
(12-23 months) 48% 50% < 50%
Time (in working days) between result of 
screening mammography and offered 
assessment 4,4 working days 5 wd 3 wd
Time (in working days) between decision 
to operate and date offered for surgery
28,7 wd 15 wd 10 wd
Performance indicators in Slovenian breast cancer screening programme Dora, 
2016.




Nadzor kakovosti dela 
radiologov – odčitovalcev v 
DORI



























Redne kontrola dela odčitovalcev
Zahteve za šolanje novih radiologov-odčitovalcev
Multidisciplinarni tečaj                              1 dan
Teoretični tečaj za odčitovalce                 2 dni
V Referenčnem centru DORA 
na Onkološkem inštitutu v Ljubljani




- poročilo vsakih 6 mesecev
1. V tem obdobju si odčital-a 9180 mamografij
2. „Recall“ za konsenz: 5,04%
(prejšnji rezultati: 5,55%; 6,07%; 5,31%; 5,67%; 6,73%; 6,15%; 6,12%)
3.  Povprečni „recall“ vseh odčitovalcev: 7,12%
(prejšnji rezultati: 7,17%; 7,95%; 7,37%; 7,26%; 7,79%; 6,86%; 6,46%)
4.  Povprečen recall po konsenzu 2,77% 
(prejšnji rezultati: 3,16%; 3,67%; 3,44%; 3,29%; 3,73%; 3,38%; 3,55%)
5.  Odkril-a si : 67 RD
6. Zgrešil-a si (napačno negativni): 2 RD
ID številke teh žensk:………
7.  Tvoja „občutljivost“ : 97% 
(prejšnji rezultati 95%; 92,98%; 100%; 98,04%; 93,55%; 96,43%; 92,59%)
8. Povprečna „občutljivost“ vseh odčitovalcev: 91,47%
9.  V tem obdobju vsi skupaj odkrili: 217 RD
10. 37 RD of 217 RD (17%) je odkril le en od dveh 
odčitovalcev 















































1 2 3 4 5 6 7 8 9 10 11 12 13
Nizi1
Zahteve za vzdrževanje izkušenosti odčitovalcev
odčitovalec letno odčitati vsaj 5000, nadzorni radiolog pa vsaj 
10.000 presejalnih mamografij
obvezna prisotnost obeh odčitovalcev na konsenzu
udeležba na pred/pooperativni konferenci
































Državni presejalni program DORA








STATISTIKA OD LETA 2010 - INŽENIRJI 
Trenutno izobraženih 102 inženirja, od tega je 
81 inženirjev aktivnih
34 DRI se je 
izobrazilo v tujini
* število brez dodatnih 
izobraževanj ali dodatnih slikanj 
po porodniški odsotnosti 
IZOBRAŽEVANJE PRI NAS:
69 DRI iz SLO
4 DRI iz Črne Gore (2 
meseca)
































30/DRI 30/DRI 30/DRI 30/DRI 30/DRI 30/DRI 
1 OI‐DORA 20 22 22 23 23 23 19 23
2 UKC MB 4 7 6 8 8 8
3 ZD MB 4 4 6 5 5
4 ZD METELKOVA 4 6 6 6 6
5 SB PTUJ 4 4




∑ DRI 20 22 26 38 39 43 45 67
∑ slik ‐ cca 640 1144 3120 4560 4680 5160 5400 8040
ŠT. DRI NA USTANOVO PO OCENJEVALNIH OBDOBJIH
CELOLETNA STATISTIKA
L. 2018 dodali 4 centre = cca 100 DRI za ocenjevanje = 12.000 slik
Usposabljanje za diplomirane 
radiološke inženirje (DRI):
• MDC (1-2dni)                                 
teoretični del
• Tečaj pozicioniranja (2dni)    
teoretični + praktični del
• Praktični del (2 tedna) 
referenčni center
Certifikat






• vsi DORA RI,
• 75 % slik 1.stopnje – skupna ocena
• 75 % slik 1.st. - za vsako posamezno 
projekcijo
• Naključno izbrane mamografske slike
• Izvajave dve RI za nadzor kakovosti
LOČENO OCENJEVANJE 
CC IN MLO-PROJEKCIJE 
OD L. 2014
cc
CC +  MLO
3
• PGMI (Anglija, Skandinavske države)





(Level 1, 2, 3)
Merila za ocenjevanje:
Moreira in sodelavci so primerjali  PGMI  in 
EAR. Ugotovili so, da so nekateri kriteriji 
pomanjkljivo opredeljeni. Obe metodi sta 
zaradi nenatančno razčlenjenih/razloženih 
napak manj zanesljivi, vendar je zanesljivost 











Naključno izberemo 30 mamografskih 
sklopov → 1 sklop = 4 mamografske slike.
Potek ocenjevanja :
4
V OCENJEVANJE NISO VKLJUČENE…
…slike, ki zaradi anatomskega vzroka 
prikažemo manj tkiva dojke oz. je kvaliteta 
slike slabša
(poškodbe rame, hrbtenice, gospe na 
invalidskih vozičkih..).
STATISTIKA 2017 









OI Ljubljana (29 DRI) 9 Dislociranih enot (52 DRI)
8520 mamogramov = 8520 odločitev












1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Inženirji
Statistika kakovosti pozicioniranja - DORA LJ















1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
DRI OI Ljubljana































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
DRI OI Ljubljana






























2 DNI SLIKANJA Z ODGOVORNIM INŽENIRJEM 
ZA NADZOR,










PRIČETEK POSTOPKA ZA PREKINITEV 
DELA V PROGRAMU DORA
TIPIČNE NAPAKE – KONTROLA 
KVALITETE…
…je pomoč inženirju pri 
spoznanju/odpravi 
napak…
…in NE iskanje napak/slabosti inženirjev!
Rutina? –





60,1 mm 68,9 mm
HVALA ZA VAŠO POZORNOST!
NIKOLI NI TAKO DOBRO, DA NE BI 















Wilson ARM et al. The requirements of a specialist breast center. Eur J Cancer, 2013
Število operacij raka dojk (vseh) v letu 2016 
po kirurgih
kirurg 1 2 3 4 5 6 7 8 9 10 11 12 13 14


















Del Turco MR et al. Quality indicators in breast cancer care. Eur J Cancer, 2010





















Priporočilo: sprejemljivo: 70% ohranitvenih, cilj: 80% ohranitvenih
































































• DEFINITIVNA HISTOLOGIJA • Reoperacije









kirurg 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Št. dgn op. 11 11 1 3 7 3 7 8 0 7 8 8 0 1
































































PATOLOG 2014 2015 2016 2017 
(do20.11.)
SKUPAJ
1. 133 178 246 269  826
2. 125 182 307 290 904
3. 186 160 235 185 766
SKUPAJ 444 520 788 744 2496
1. Število biopsij na patologa
B.  Število kirurških biopsij (ekscizij ali resekcij)/patologa/leto (minimalno 100)
PATOLOG 2015 2016 2017
(do 20.11.)
SKUPAJ
1. 201 179 182 562
2. 157 193 155 505
3. 96 149 136 381
4. 92 179 189 460
5. 112 160 161 433
6. 192 230 253 675
7. 176 225 181 582













PATOLOG < 5 dni (%) < 7 dni (%) < 10 dni (%) AVG MEDIANA
1. 100% 100% 100% 1,78 2
2. 98,28% 100% 100% 2,66 3
3. 98,38% 100% 100% 1,62 1
2. Čas od sprejema vzorca do avtorizacije izvida (TAT)
B. TAT ekscizije in resekcije (8 patologov)
Priporočila: < 5 dni    80%
< 7 dni    90%
< 10 dni  100%
mediana  4 dni
PATOLOG < 5 dni (%) < 7 dni (%) < 10 dni (%) AVG (dni) MEDIANA
najhitrejši 88, 8 % 97,2% 99,4% 4,1 4

















Datum Patolog Datum Patolog




EVIDENCA POPRAVKOV IZVIDAOddelek  za patologijo
Zaporedna št. 
vpisa Bx

































































































































90% > 90 % 98,6 96,9
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